Acorai

🌟Acorai at CSI FOCUS D-HF: Join Us in Frankfurt!🌟 We’re excited to share Acorai’s progress in non-invasive cardiovascular care at this year’s CSI FOCUS D-HF, paving the way for advancements in heart failure management. 📅 Event Dates: December 13-14, 2024 🎙️ Join the Conversation Our CEO, Filip Peters, will present on Saturday, December 14th (13:30 – 14:50 CET), discussing how Acorai’s approach offers reliable, actionable data as a non-invasive alternative to traditional methods. 📍 Let’s Connect! Heading to Frankfurt? We look forward to seeing you there! Interested in exploring how Acorai is advancing heart failure management with non-invasive innovation?   🤝 Book a meeting with Filip here: https://lnkd.in/dAdW6TXf #CSIDHF2024 #csicongress #HeartFailure #MedTech #Acorai 

Excited to Share a Milestone: Acorai Secures $4.5M Investment from the EIC Fund! 🙌 🤝 "We are proud to welcome the EIC Fund as a strategic partner for Acorai at this transformative stage. With this investment and more than $6M in additional provisioned funding, Acorai is scaling its clinical and regulatory efforts, paving the way to market our solution and positively impact over 60 million heart failure patients globally." - Filip Peters (Acorai CEO) 🫀 This funding enables us to complete clinical studies, prepare regulatory submissions in the U.S. and Europe, and take crucial steps toward the commercialization of our non-invasive heart failure technology. 💪 With this latest investment, Acorai's seed funding totals $8.5M, enabling us to continue develop our product and generate the evidence needed for regulatory approvals and adoption. 📜 About the EIC Fund: The European Innovation Council (EIC) Fund is a unique initiative by the European Commission that invests in visionary companies developing breakthrough innovations across deep tech sectors. Focused on fostering transformational change, the EIC Fund bridges the gap between research, innovation, and market uptake by combining equity investments with grant funding. European Innovation Council and SMEs Executive Agency (EISMEA) 🔗 Find out more of the full announcement on our website: https://lnkd.in/dnc3JKD6  #Acorai #EUeic #eicAccelerator #HeartFailure #MedTech

🌟 We’re Honored! 🌟 We extend our heartfelt congratulations to the winners and all the incredible finalists in the "HealthTech Company of the Year, 2024" by the European Lifestars Awards - Celebrating Life Science Leaders! 🎉  This recognition reinforces our commitment to advancing heart failure management through non-invasive innovation. Here’s to pushing boundaries and shaping the future of healthcare—together! 🌍 ❤️ #HealthTech #LifestarsAwards #Acorai #EUeic #eicAccelerator #HeartFailure #MedTech

Learn more about how Acorai is advancing heart failure management with our non-invasive SAVE Sensor System. ❤️ Who We Are: Acorai is dedicated to advancing non-invasive cardiovascular care, focused on improving patient outcomes and empowering clinicians with next-generation technology for enhanced patient management. ⚠️Key Problem: Heart failure patients are difficult to manage, accounting for high costs and readmission rates. Managing patients with cardiac and pulmonary pressures improves patient outcomes, but existing solutions are costly and invasive. 🏅Our Solution: SAVE Sensor System - Seismic (SCG), Acoustic (PCG), Visual (PPG), Electric (ECG)  Acorai’s patented SAVE Sensor System integrates multiple sensing technologies—seismocardiograpy, phonocardiography, photoplethysmography and electrocardiography —into a single device, trained on thousands of measurements from the gold standard: Right heart catheterization. Our multi-modal sensing platform was FDA Breakthrough Device designated in 2023, granting us access to the FDA Total Product Life Cycle Advisory Program (TAP) Pilot. 🤝Join Us on This Journey: Acorai is dedicated to shaping the future of cardiac care through non-invasive innovation. If you’re interested in our vision, let’s connect! We welcome opportunities to collaborate, partner, and share our journey with those equally committed to improving patient care. Book a meeting with Filip Peters: 👇https://lnkd.in/ejGWThtb LSI LSI Europe #LSIEurope24 #HeartFailure #MedTech #CardiacCare #NonInvasiveTech #Acorai  #EUeic #eicAccelerator

CAPTURE-HF study enrollment complete.

🌟 Big News from Acorai! 🌟 We’re thrilled to announce the successful enrollment completion of our CAPTURE-HF study – 1,600 patients across 20 clinical sites in six countries. This marks a major step in advancing heart failure management through non-invasive innovation. A huge thank you to our incredible clinical team and esteemed partners and investigators for their commitment to making this milestone possible. Together, we’re committed to shaping the future of cardiac care with non-invasive technology. 👉 What’s next? Results are expected in early 2025, setting the stage for regulatory submissions in the U.S. and Europe and bringing us closer to transforming cardiac care worldwide. 🔗 Check out our full announcement on our website: https://lnkd.in/d743nmyJ Sahlgrenska University Hospital, Skånes universitetssjukhus (Skåne University Hospital), St Luke's Hospital of Kansas City, Conway Regional Cardiovascular Clinic, BAPTIST HEALTH MEDICAL CENTER - LITTLE ROCK, Cleveland Clinic Martin Health, Medical University of South Carolina, Mayo Clinic, University of Toronto - Mt Sinai, Royal Brompton and Harefield hospitals, Southampton University Hospital, OLV Ziekenhuis Aalst-Asse-Ninove, Rigshospitalet, Duke Clinical Research Institute, Medical University of South Carolina, University of Ottawa Heart Institute #HeartFailure #CardiacCare #CAPTUREHF #Acorai  #EUeic #eicAccelerator #MedTech

Thank you for bringing more awareness to the (often overlooked) issues within heart failure Mike Moore. Hopefully we’ll see non-invasive cardiac and pulmonary sensing devices on that list soon!

📅 Save the Date! We’re excited to share that Filip Peters (CEO of Acorai), will be representing Acorai at the CSI FOCUS D-HF 2024 focused on Device-Based Therapy in Heart Failure. Join our session on Saturday, December 14th, from 13:30 to 14:50 CET, to catch our insights on how non-invasive cardiac and pulmonary pressure sensing is set to transform heart failure therapy. Don’t miss out – add the session to your calendar and stay ahead with the latest in cardiovascular innovation. 📅 Excited to connect with everyone in CSI Focus D-HF: December 13-14, 2024 Frankfurt, Germany 🔗https://lnkd.in/d7wGDXKw #CSIDHF2024 #csicongress #HeartFailure #MedTech #CardiacMonitoring #Acorai

4,461 miles away from home on the weekend in Arkansas! What would you do in my shoes? 🥾 This week, I had the privilege of collaborating with Anthony Carnicelli and Ryan Tedford at Medical University of South Carolina, followed by a visit to Conway Regional Health System. Exciting news - CAPTURE-HF, Acorai's non-invasive pulmonary artery, and cardiac pressure sensing device, exceeded its 1500 participant goal. Time to dive into closing the study and analyzing the data! 🔬 How does this relate to hiking in the Ozarks? 🏞️ Next on the agenda is meeting with Andrew J. Sauer, MD at Saint Luke's Mid America Heart Institute, and Darshan Brahmbhatt at Mount Sinai Hospital (Toronto), Sinai Health. From Conway, AR, to Kansas City, MO, I drove and decided to spend a Saturday trekking 18 miles through the stunning trees and boulders of a state park. Can't wait to see the outcomes of CAPTURE-HF Acorai! What other adventures could I have experienced in the wilderness between AR and MO? comment below 👇

Acorai is happy to be among the Top 10 Finalist in the Chronic Disease Management category at the #HTC2024! We are looking forward to the #HealthTechForward2024 in Barcelona between the 4-5th December!